sodium phenylbutyrate 916.7mg5ml oral solution
special order - sodium phenylbutyrate - oral solution - 183.34mg/1ml
pheburane 483mgg granules
lucane pharma ltd - sodium phenylbutyrate - granules - 483mg/1gram
sodium phenylbutyrate 625mg5ml oral solution
special order - sodium phenylbutyrate - oral solution - 125mg/1ml
sodium phenylbutyrate 1.83g5ml oral solution
special order - sodium phenylbutyrate - oral solution - 366mg/1ml
sodium phenylbutyrate 1.25g5ml oral solution
special order - sodium phenylbutyrate - oral solution - 250mg/1ml
pheburane
orpharma nz limited - sodium phenylbutyrate 84 g equivalent to 483 mg of sodium phenylbutyrate per gram of granules; ; - oral granules - 483 mg - active: sodium phenylbutyrate 84 g equivalent to 483 mg of sodium phenylbutyrate per gram of granules excipient: ethylcellulose hypromellose macrogol 1500 povidone sugar spheres - pheburane is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. pheburane should be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, and protein-free calorie supplements). pheburane is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. geriatrics (> 65 years of age): pheburane has not been studied in the geriatric population.